Thalomid — Competitive Intelligence Brief

Thalomid (THALIDOMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: thalidomide. Area: Oncology.

marketed thalidomide Tumor necrosis factor Oncology Small molecule

Target snapshot

Thalomid (THALIDOMIDE) — Bristol-Myers Squibb. Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Thalomid TARGET	THALIDOMIDE	Bristol-Myers Squibb	marketed	thalidomide	Tumor necrosis factor	1998-01-01
Elrexfio	elranatamab-bcmm	Pfizer	marketed		Tumor necrosis factor receptor superfamily member 17	2023-01-01
Trulance	PLECANATIDE	Salix	marketed	Guanylate Cyclase-C Agonist [EPC]	Tumor necrosis factor	2017-01-01
Lymphostat B	BELIMUMAB	Human Genome Sciences Inc.	marketed	B Lymphocyte Stimulator-specific Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 13B	2011-01-01
Prolia	DENOSUMAB	Amgen	marketed	RANK Ligand Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 11	2010-01-01
Simponi	GOLIMUMAB	Centocor Ortho Biotech Inc	marketed	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	2009-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01

Recent regulatory actions (last 90 days)

• 2026-02-19 — Elrexfio · FDA · approved · US · Pfizer

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (thalidomide class)

1. Bristol-Myers Squibb · 1 drug in this class